Novartis Awaits FDA Action On Aclasta After “Approvable” Letter For Paget’s Disease
This article was originally published in The Pink Sheet Daily
Novartis is waiting to hear back from FDA on the status of zoledronic acid for the treatment of Paget's disease of the bone after responding to an "approvable" letter from the agency
You may also be interested in...
FDA is seeking additional information from ongoing osteoporosis trials of the zoledronic acid for treatment of Paget's disease.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.